Key facts
- It has raised $14.8M; the latest was Early Stage VC in Mar 2025.
- Notable investors include Wuxi Capital Group, Fosun Health Capital, Tahoe Venture, Yao Pharma, Zhejiang Huahai Pharmaceutical.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Starmab Biologies
- ·The full record, as it builds
Funding rounds
No funding rounds for Starmab Biologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Starmab Biologies
Developer of anti-infective macromolecule medicines designed for fungi, bacteria and viruses. The company focuses on antibody drug discovery, pharmaceutical research system and development capabilities, enabling to solve clinical problems that cannot be solved by existing anti-infective drugs.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
Starmab Biologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Starmab Biologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Starmab Biologies in its N-PORT filings yet. We sweep new filings monthly.